Last reviewed · How we verify
non-biologic anti-rheumatic drugs
At a glance
| Generic name | non-biologic anti-rheumatic drugs |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines (PHASE3)
- A Study of Clinical and Immune Responses to Sequential Biologic Therapies in Psoriatic Arthritis
- Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases (PHASE4)
- A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) (PHASE3)
- AScalate: Treat-to-target in Axial Spondyloarthritis (PHASE3)
- A Study of Iguratimod in Combination With Tofacitinib in RA Patients (PHASE4)
- Safety Study of Abatacept to Treat Rheumatoid Arthritis
- A Study to Characterize Profile of Participant With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- non-biologic anti-rheumatic drugs CI brief — competitive landscape report
- non-biologic anti-rheumatic drugs updates RSS · CI watch RSS
- Pfizer portfolio CI